Company news

OncoSil Medical Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Activities/Appendix 4C Cash Flow Report

July 29, 2022

Patient treated in Spain proceeds to successful resection

July 18, 2022

Bupa UK Approves Reimbursement for OncoSil in the UK

July 3, 2022

FY 2023 Strategic Update

June 29, 2022

OncoSil PanCO Clinical Trial Presented At ESMO World WCGIC

June 28, 2022

Entitlement Offer Results and Shortfall Notification

June 9, 2022

OncoSil Entitlement Offer Booklet

May 10, 2022

Clarification Of Non-Renouncable Entitlement Offer Details

May 1, 2022

OncoSil Launches $10m Capital Raising

April 29, 2022

OncoSil Signs Commercial Agreement With Hospital In Spain

April 28, 2022

First Commerical Pancreas Treatment In Spain

April 12, 2022

Fully-Funded Trial Approved In Germany

March 27, 2022

Half Yearly Report Results

February 22, 2022

OncoSil approved for Innovation Funding (NUB) in Germany

February 2, 2022

PanCO Clinical Study on OncoSil Published in ESMO Open

December 23, 2021

2021 AGM CEO Presentation

October 18, 2021

Receipt of $1.077m R&D Tax Incentive Refund

September 26, 2021

OncoSil TGA regulatory update

June 2, 2021

OncoSil receives regulatory approval from Hong Kong

May 4, 2021

Appendix 4C - quarterly

April 29, 2021

OncoSil Investor Update

February 17, 2021

Appointment of Chief Executive Officer

January 21, 2021

OncoSil FY21 half yearly review

January 18, 2021

Termination of Mr Daniel Kenny as Chief Executive Officer

December 1, 2020

OncoSil receives Swiss regulatory approval

November 4, 2020

OncoSil achieves first commercial sale

October 21, 2020

Positive PanCO trial update on resected cohort

October 19, 2020

Receipt of $2.8m R&D Tax Incentive Refund

September 22, 2020

Investor Update

August 28, 2020

OncoSil receives Malaysian regulatory approval

August 27, 2020

Preliminary Final Report - Appendix 4E Announcement

August 19, 2020

HDE filing submitted in US for Bile Duct Cancer treatment

July 27, 2020

OncoSil presents clinical data at ESMO World Congress

July 3, 2020

OncoSil files for TGA registration

July 1, 2020

OncoSil receives Singapore regulatory approval

May 31, 2020

Allotment of Securities under Institutional Placement

May 7, 2020

Proposed issue of Securities - OSL

May 3, 2020

Oncosil breakthrough device receives CE Marking approval

March 31, 2020

Clarification Statement

March 27, 2020

Pause in Trading

March 26, 2020

FDA Grants Breakthrough Device Designation

March 17, 2020

CE Mark Update

November 18, 2019

Positive CE Mark Status Report

October 31, 2019

OncoSil AGM CEO Presentation

October 28, 2019

Receipt of $3.8M R&D Tax Incentive

October 17, 2019

Appendix 4E and Full Year Statutory Accounts

August 23, 2019

Response to ASX Price Query

July 26, 2019

Update - CE Marking Application

March 28, 2019

CE Marking Update

March 24, 2019

PanCo Study Interim Analysis

October 24, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 41 decks. Every deck is listed under its year.